Market Overview

UPDATE: J.P. Morgan Upgrades NxStage Medical to Overweight


J.P. Morgan is out with its report today on NxStage Medical (NASDAQ: NXTM), upgrading NXTM from Neutral to Overweight.

In a note to clients, J.P. Morgan writes, "We are upgrading shares of NxStage Medical from Neutral to Overweight. NxStage shares are off sharply since the 1Q EPS call in early May, driven largely by concerns that a key customer (Fresenius) is restricting the number of patients it will support on home hemodialysis. We view concerns at this point as overdone, based on: (1) our survey work, which suggests sustainable 30% growth for the U.S. HHD market over the next few years; (2) our view that any restrictive behavior by FME will be (a) manageable (with FME representing <10% of home sales) and (b) short term in nature; and (3) the potential for clarification of the Medicare home reimbursement process in the next 24 months (and possibly as early as this summer), improving access to HHD."

J.P. Morgan maintains a $26 PT on NXTM.

Shares of NXTM closed Thursday at $17.85, up 2.94% from Wednesday's close.

Posted-In: J.P. Morgan NxStage MedicalAnalyst Color Upgrades Analyst Ratings


Related Articles (NXTM)

View Comments and Join the Discussion!

Latest Ratings

DAVACantor FitzgeraldMaintains46.0
TDGCredit SuisseMaintains623.0
BRYTudor PickeringDowngrades11.0
NTNXOTR GlobalUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Goldman Sachs Raises PT To $76 On BF-B

Rodman & Renshaw Terminates Coverage of China Automotive Systems